Cure My Disease

Don't miss your cure!

 Log in / Sign up

New targeted pill holds promise for rare salivary gland cancer that spreads

NCT ID NCT07682675

Not yet recruiting Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This phase 2 trial tests the drug zanzalintinib in people whose adenoid cystic carcinoma (a rare salivary gland cancer) has returned or spread. Despite initial surgery and radiation, about half of patients experience recurrence, and current treatments offer limited benefit. Participants take a daily pill of zanzalintinib to see if it can shrink tumors or slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
zanzalintinib (a targeted therapy taken as a daily pill)
What this could lead to
If effective, zanzalintinib could offer a new treatment option for people with recurrent or metastatic adenoid cystic carcinoma, a rare cancer with few effective therapies.
What could go wrong
This is a small, early-phase trial (51 participants) without a comparison group. The drug may not shrink tumors or improve outcomes, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA OF THE HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma metastatic neoplasm Neoplasm Metastasis Recurrence salivary gland adenoid cystic carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOID CYSTIC CARCINOMA OF THE SALIVARY GLAND METASTATIC DISEASE RECURRENCE

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Gustave Roussy

    Villejuif, 94800, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Oncopole Claudius Regaud

    Toulouse, 31052, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.